Redmile Group LLC lessened its stake in Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report) by 52.2% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 772,126 shares of the company’s stock after selling 844,102 shares during the quarter. Redmile Group LLC’s holdings in Pliant Therapeutics were worth $973,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Invesco Ltd. raised its holdings in Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company’s stock valued at $93,000 after acquiring an additional 20,449 shares in the last quarter. Royal Bank of Canada grew its holdings in Pliant Therapeutics by 222.4% during the 1st quarter. Royal Bank of Canada now owns 362,702 shares of the company’s stock worth $491,000 after acquiring an additional 250,185 shares in the last quarter. AQR Capital Management LLC acquired a new position in Pliant Therapeutics during the 1st quarter worth approximately $97,000. Goldman Sachs Group Inc. increased its position in shares of Pliant Therapeutics by 6.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company’s stock valued at $642,000 after purchasing an additional 29,177 shares during the last quarter. Finally, Woodline Partners LP increased its position in shares of Pliant Therapeutics by 1,875.0% in the 1st quarter. Woodline Partners LP now owns 2,514,084 shares of the company’s stock valued at $3,394,000 after purchasing an additional 2,386,789 shares during the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.
Pliant Therapeutics Stock Performance
Shares of NASDAQ PLRX opened at $1.07 on Wednesday. The stock’s 50-day simple moving average is $1.15 and its 200-day simple moving average is $1.22. The firm has a market capitalization of $66.25 million, a PE ratio of -0.58 and a beta of 1.21. Pliant Therapeutics, Inc. has a fifty-two week low of $1.05 and a fifty-two week high of $1.95.
Analyst Ratings Changes
PLRX has been the subject of several recent analyst reports. Wall Street Zen raised shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 19th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $3.00.
View Our Latest Research Report on PLRX
Pliant Therapeutics Profile
Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.
The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).
Featured Stories
- Five stocks we like better than Pliant Therapeutics
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding PLRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pliant Therapeutics, Inc. (NASDAQ:PLRX – Free Report).
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
